For an acute hidradenitis suppurativa flare, should treatment be oral therapy or topical medication?

Treatment of Acute Hidradenitis Suppurativa Flare: Oral vs Topical Therapy

For an acute HS flare, oral systemic antibiotics are the preferred first-line treatment over topical therapy alone, with intralesional triamcinolone as a valuable adjunct for individual inflamed lesions. 1, 2

Rationale for Oral Therapy in Acute Flares

The evidence strongly supports systemic antibiotics for acute flares because:

• Topical clindamycin has limited efficacy: The only RCT of topical clindamycin in HS showed it reduced pustules but had no effect on inflammatory nodules and abscesses—the hallmark lesions of an acute flare 1

• Systemic antibiotics address deeper inflammation: Acute flares involve deep-seated nodules and abscesses that topical agents cannot adequately penetrate 1

• Expert practice confirms this approach: A 2024 survey of HS experts found 100% use systemic antibiotics for flare management, while topical agents were not prominently featured 3

Recommended Oral Regimens for Acute Flares

First-line oral options (choose based on disease severity):

• Tetracyclines (doxycycline or lymecycline) for at least 12 weeks in mild-to-moderate flares 2
• Clindamycin 300 mg + rifampin 300 mg twice daily for 10-12 weeks in patients unresponsive to tetracyclines or with more severe flares 2, 4

Short-term adjuncts for severe acute inflammation:

• Oral corticosteroids for rapid symptom control (68.6% of experts use this) 3, 4
• Intralesional triamcinolone 10 mg/mL (0.2-2.0 mL) into individual inflamed lesions provides significant pain reduction within 1 day and reduces erythema, edema, and suppuration 1—91.4% of experts use this approach 3

Limited Role for Topical Therapy in Acute Flares

Topical clindamycin 1% may be considered as an adjunct only, not monotherapy, because:

• It performed similarly to oral tetracycline in mild-to-moderate disease but showed no benefit for nodules/abscesses 1
• It increases Staphylococcus aureus resistance rates 1
• The 2026 AAD-HSF guidelines give it only a conditional recommendation even in general HS management 4

Topical therapy is best reserved for maintenance between flares or very mild disease with only pustules, not for acute inflammatory flares with nodules and abscesses.

Critical Pitfalls to Avoid

• Do not rely on topical antibiotics alone for nodular/abscess flares—they lack penetration and efficacy for deep inflammation
• Do not delay systemic therapy waiting for topical agents to work in moderate-to-severe flares
• Combine intralesional steroids with systemic therapy rather than using either alone for optimal rapid symptom control
• Address pain aggressively: 91.4% of experts use nonprescription pain relievers and 71.4% use prescription analgesics during flares 3

Treatment Algorithm for Acute Flares

1. Assess flare severity (presence of nodules, abscesses, extent)
2. Mild flare (few pustules, no nodules): Consider topical clindamycin + oral tetracycline
3. Moderate-to-severe flare (nodules, abscesses): Start oral clindamycin + rifampin OR oral tetracycline + consider short-term oral corticosteroids
4. Individual large inflamed lesions: Add intralesional triamcinolone for rapid pain relief
5. Pain management: Prescribe analgesics routinely 4
6. Reassess at 10-12 weeks: If inadequate response, escalate to biologics (adalimumab, secukinumab, or bimekizumab) 4

The evidence base consistently demonstrates that acute HS flares require systemic intervention to address the deep inflammatory process, with topical therapy playing at best a supplementary role.